clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Stjepanovic MI et al. Pulmonary and Vertebral Mycobacterium avium Disease in a HIV-negative 71-year-old Man - A Case Report. 2016 Infez Med pmid:28011973
Muñoz-Egea MC et al. Effect of Antibiotics and Antibiofilm Agents in the Ultrastructure and Development of Biofilms Developed by Nonpigmented Rapidly Growing Mycobacteria. 2016 Microb. Drug Resist. pmid:26208145
Chauffour A et al. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. 2016 PLoS Negl Trop Dis pmid:27755552
Abuhammour A et al. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. 2016 Arab J Gastroenterol pmid:27665525
Matsumoto H et al. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. 2016 Dig. Dis. Sci. pmid:27659671
Rossi A et al. Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. 2016 Drug Dev Ind Pharm pmid:26065531
Christianson S et al. Time-to-Detection of Inducible Macrolide Resistance in Mycobacterium abscessus Subspecies and Its Association with the Erm(41) Sequevar. 2016 PLoS ONE pmid:27490181
Harada T et al. Premedication with Clarithromycin Is Effective against Secondary Bacterial Pneumonia during Influenza Virus Infection in a Pulmonary Emphysema Mouse Model. 2016 J. Pharmacol. Exp. Ther. pmid:27489022
Bonfigli AR et al. Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. 2016 Nutr Metab Cardiovasc Dis pmid:27480449
Chung JW et al. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. 2016 Dig Liver Dis pmid:27257049
Mitchell H and Katelaris P Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. 2016 Med. J. Aust. pmid:27256648
Ullah S et al. Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. 2016 Drug Deliv pmid:27247018
Song ZQ et al. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. 2016 Chin. Med. J. pmid:27064046
Matsumoto H et al. Molecular Detection of H. pylori Using Adherent Gastric Mucous to Biopsy Forceps. 2016 Helicobacter pmid:27061611
Tsaganos T et al. Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. 2016 Antimicrob. Agents Chemother. pmid:27044546
Franceschi F et al. High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. 2016 Eur Rev Med Pharmacol Sci pmid:26875899
Tepeš B et al. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. 2016 Eur J Gastroenterol Hepatol pmid:26862930
Lim SG et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. 2016 Dig Liver Dis pmid:26856963
Vermeer LM et al. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. 2016 Drug Metab. Dispos. pmid:26668209
Meng Y et al. Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. 2016 Pharm. Res. pmid:26666773
Kamiya K et al. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. 2016 J. Dermatol. pmid:26508502
Mark TM and Coleman M It's Time to Take Clarithromycin Seriously in Multiple Myeloma. 2016 Acta Haematol. pmid:26505907
Qiu XH et al. Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. 2016 Acta Haematol. pmid:26505646
Takagi M et al. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. 2015 Drug Metab. Pharmacokinet. pmid:26195223
Li Y et al. Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistant Staphylococcus aureus infection. 2015 Drug Deliv pmid:24471983
Jung IY et al. A case of bronchiolitis obliterans organizing pneumonia in an HIV-infected Korean patient successfully treated with clarithromycin. 2015 BMC Infect. Dis. pmid:26201392
Sobajima T et al. A Case of Pulmonary Actinomycosis Associated With Aspiration of Cedar Leaves. 2015 J Bronchology Interv Pulmonol pmid:26165898
Gunjan S et al. Clarithromycin enhances the antimalarial efficacy of mefloquine via its increased bioavailability and disrupting P. falciparum apicoplast. 2015 Life Sci. pmid:26164186
Zeng M et al. Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study. 2015 BMC Immunol. pmid:26047816
Converse PJ et al. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. 2015 PLoS Negl Trop Dis pmid:26042792
Klain V and Timmerman L Comment on The dangers of gastritis: a case of clarithromycin-associated brief psychotic episode. 2015 J. Nerv. Ment. Dis. pmid:26034875
Prapitpaiboon H et al. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. 2015 Asian Pac. J. Cancer Prev. pmid:26028098
Kim JS et al. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis. 2015 J. Gastroenterol. Hepatol. pmid:25867718
Heo J et al. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. 2015 J. Gastroenterol. Hepatol. pmid:25867608
Sugita S et al. EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells. 2015 Biochem. Biophys. Res. Commun. pmid:25858318
Cowan R et al. Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients? 2015 PLoS Negl Trop Dis pmid:25658304
Brown-Elliott BA et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. 2015 J. Clin. Microbiol. pmid:25653399
Iino Y et al. Clinical effects of clarithromycin on persistent inflammation following Haemophilus influenzae-positive acute otitis media. 2015 Acta Otolaryngol. pmid:25649881
Kam Y et al. Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges". 2015 Int. J. Cancer pmid:25156304
Yildizoglu U et al. Effect of antibiotic use on bacterial flora of tonsil core in patients with recurrent tonsillitis. 2015 Eur Arch Otorhinolaryngol pmid:25510984
Jiang F et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. 2015 Psychopharmacology (Berl.) pmid:25510856
Frew JW and Nguyen RT Tattoo-associated mycobacterial infections: an emerging public health issue. 2015 Med. J. Aust. pmid:26852055
Keshavarz Azizi Raftar S et al. The Helicobacter pylori resistance rate to clarithromycin in Iran. 2015 Microb. Drug Resist. pmid:25144338
Namkoong H et al. Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report. 2015 BMC Pulm Med pmid:26496968
Wang CH et al. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. 2015 World J. Gastroenterol. pmid:26494972
Buch T and Andersen SE [Combination therapy with fluconazole and other QTc-prolonging drugs increase the QTc interval]. 2015 Ugeskr. Laeg. pmid:26471025
Kiesewetter B et al. Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma. 2015 J. Clin. Oncol. pmid:24778391
Yin SM et al. Disseminated Mycobacterium kansasii disease in complete DiGeorge syndrome. 2015 J. Clin. Immunol. pmid:26048260
Nakamura M et al. Clarithromycin ameliorates pulmonary inflammation induced by short term cigarette smoke exposure in mice. 2015 Pulm Pharmacol Ther pmid:26363279
Brusselle GG Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases? 2015 Thorax pmid:25870311